Use your antibodies-online credentials, if available.
抗Mouse (Murine) POLE 抗体:
抗Human POLE 抗体:
抗Mustelid POLE 抗体:
Human Monoclonal POLE Primary Antibody for ICC, IF - ABIN151041
Maga, Jónsson, Stucki, Spadari, Hübscher: Dual mode of interaction of DNA polymerase epsilon with proliferating cell nuclear antigen in primer binding and DNA synthesis. in Journal of molecular biology 1999
Show all 12 Pubmed References
A missense mutation in Rev7 (显示 MAD2L2 抗体) disrupts formation of Polzeta, impairing mouse development and repair of genotoxic agent-induced DNA lesions.
This is the first study to functionally analyze a POLE genetic variant outside the exonuclease (显示 EXO1 抗体) domain and widens the spectrum of genetic changes in this DNA polymerase (显示 POLB 抗体) that could lead to colorectal cancer predisposition.
POLE exonuclease (显示 EXO1 抗体) domain mutations are prognostic markers associated with excellent outcomes for endometrial carcinoma patients.
Germline PMS2 (显示 PMS2 抗体) and somatic POLE exonuclease (显示 EXO1 抗体) mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours
Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 (显示 PDCD1 抗体) blockade
Human CTF18-RFC clamp-loader complexed with non-synthesising POLE efficiently loads the PCNA sliding clamp.
POLE-mutated undifferentiated and dedifferentiated endometrial carcinomas were more frequently stage I tumors than similar carcinomas lacking exonuclease (显示 EXO1 抗体) domain mutations (7/9; 78% vs. 3/12; 25%; P=0.023) and patients had significantly better outcome (disease-specific survival) than those without POLE exonuclease (显示 EXO1 抗体) domain mutations (P=0.02)
Germline or somatic variants in the POLE/POLD1 (显示 POLD1 抗体) were identified in unresolved suspected Lynch syndrome cancers with mismatch repair defect.
In colorectal cancers, mutations in the FBXW7 gene were more common in the younger cohort (27.5% vs 9.7%; P = .0022) as were mutations in the proofreading domain of polymerase epsilon catalytic subunit (POLE) (9.8% vs 1%; P = .0048).
POLE ultra-mutated endometrial-carcinomas are heavily infiltrated with CD4 (显示 CD4 抗体)+/CD8 (显示 CD8A 抗体)+ TIL (显示 TLR1 抗体), overexpress PD-1 (显示 PDCD1 抗体) immune-check-point, and have a better prognosis when compared to other molecular subtypes of endometrial-carcinomas patients. POLE-mutated tumor-cell lines are resistant to platinum-chemotherapy in-vitro suggesting that the better prognosis of POLE-patients is not secondary to a higher sensitivity to ch
Tumors with POLE EDMs had the most favorable prognosis, and those with p53 (显示 TP53 抗体) abn the worst prognosis, and separation of the 2 middle survival curves (p53 (显示 TP53 抗体) wt and MMR (显示 MRC1 抗体)-D) was observed
Participates in DNA repair and in chromosomal DNA replication.
DNA polymerase II subunit A
, DNA polymerase epsilon catalytic subunit A
, DNA-directed DNA polymerase epsilon